Circurna is a biotechnology company developing next-generation RNA therapeutics using its proprietary ciRNA™ circular RNA platform. Our team brings deep knowledge across RNA biology, immunology, oncology, clinical development, regulatory strategy, and intellectual property, with a shared focus on building RNA therapeutics that are durable, practical, and scalable for real-world use.
The breadth of Circurna’s technology enables rapid design, production, and administration of circular RNA-based therapies—delivering proprietary solutions across the entire development spectrum with unprecedented speed.
Designed to move fast. Built to scale. Driven by data.
Our platform development is supported through selective collaborations spanning AI-driven discovery, advanced delivery technologies, and GMP manufacturing. Circurna retains ownership of its platform and intellectual property while working with partners to accelerate execution and reduce operational risk.
Empowering the Future of Therapeutics with Circular RNA Innovation
